The price of Plus Therapeutics Inc (NASDAQ:PSTV) shares last traded on Wall Street rose 24.97% to $0.98.
PSTV stock price is now 2.43% away from the 50-day moving average and -23.31% away from the 200-day moving average. The market capitalization of the company currently stands at $16.72M.
With the price target of $9, D. Boral Capital recently initiated with Buy rating for Plus Therapeutics Inc (NASDAQ: PSTV). On January 25, 2021, Ladenburg Thalmann recently initiated its ‘Buy’ rating on the stock quoting a target price of $8, while ‘Maxim Group’ rates the stock as ‘Buy’
In other news, Hawkins Richard J, Director bought 4,000 shares of the company’s stock on Sep 13 ’24. The stock was bought for $5,996 at an average price of $1.50. Upon completion of the transaction, the Director now directly owns 15,188 shares in the company, valued at $14884.24. An SEC document containing details of the transaction can be found on the SEC’s website. On Sep 12 ’24, Director Hawkins Richard J bought 6,285 shares of the business’s stock. A total of $8,512 was incurred on buying the stock at an average price of $1.35. This leaves the insider owning 11,188 shares of the company worth $10964.24. A total of 2.55% of the company’s stock is owned by insiders.
During the past 12 months, Plus Therapeutics Inc has had a low of $0.24 and a high of $2.67. The fifty day moving average price for PSTV is $0.9652 and a two-hundred day moving average price translates $1.2855 for the stock.
The latest earnings results from Plus Therapeutics Inc (NASDAQ: PSTV) was released for 2024-12-31. The company reported revenue of $1.41 million for the quarter, compared to $1.31 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 7.54 percent.
